• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Divi’s, Gland, Fidelity enter race to buy Orchid Pharma

firstwordpharmaMarch 04, 2019

Tag: Divi’s , Fidelity , Orchid Pharma , Gland

  • The Economic Times reported that Divi's Laboratories, Divi’s Laboratories Gland Celsus Bio Chemicals and Fidelity Trading Corporation have shown preliminary interest in taking over Orchid Pharma.

  • Other bidders keen to acquire the bulk cephalosporin drugmaker include financial investors Everstone, Piramal Capital, AION Capital, ART Capital and Finquest Group.

  • The news comes after the Chennai bench of the National Company Law Tribunal (NCLT) knocked back a proposal by Ingen Capital to take over Orchid Pharma after it failed to bring in the requisite money.

Register as Visitor to CPhI China 2019!

Previous:Pharma Can BMS rebels scuttle its Celgene buy? Analysts do the math—and so far, the votes don't add up

Next:Eli Lilly to launch authorised Humalog generic in the US at 50-percent lower list price

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Divi’s, Gland, Fidelity enter race to buy Orchid Pharma | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Prostaglandin intermediate42542-01-8

Prostaglandin intermediate42542-01-8
Prostaglandin intermediate31753-00-1

Prostaglandin intermediate31753-00-1
Prostaglandin intermediate101849-78-9

Prostaglandin intermediate101849-78-9
Prostaglandin intermediate59619-81-7

Prostaglandin intermediate59619-81-7
Prostaglandin intermediate62561-03-9

Prostaglandin intermediate62561-03-9
Prostaglandin intermediate38231-86-6

Prostaglandin intermediate38231-86-6
Prostaglandin intermediate83470-76-2

Prostaglandin intermediate83470-76-2
Prostaglandin intermediate55444-68-3

Prostaglandin intermediate55444-68-3
Prostaglandin intermediate104121-92-8

Prostaglandin intermediate104121-92-8
Prostaglandin intermediate178454-81-4

Prostaglandin intermediate178454-81-4

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service